Literature DB >> 16999671

Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis.

Michelle J Irving1, Jonathan C Craig, Martin Gallagher, Stephen McDonald, Kevan R Polkinghorne, Rowan G Walker, Simon D Roger.   

Abstract

OBJECTIVE: To evaluate the outcomes of and barriers to implementing standard guidelines (Caring for Australasians with renal impairment [CARI]), using iron management in patients having dialysis as an example. DESIGN AND
SETTING: On-site review of iron management processes at six Australian dialysis units varying in size and locality. Patients' iron indices and haemoglobin levels were obtained from the Australian and New Zealand Dialysis and Transplant Registry. PARTICIPANTS: Patients with chronic kidney disease who were dependent on dialysis. MAIN OUTCOME MEASURES: Processes for assessing indices of iron stores and iron supplementation; comparison with target indices in the CARI guidelines.
RESULTS: There was considerable variability among the units in achievement of haemoglobin and iron targets, with 25%-32% of patients achieving haemoglobin targets of 110-120 g/L, 30%-68% achieving ferritin targets of 300-800 microg/L, and 65%-73% achieving transferrin saturation targets of 20%-50%. Implementation barriers included lack of knowledge, lack of awareness of or trust in the CARI guideline, inability to implement the guideline, and inability to agree on a uniform unit protocol. Factors associated with achieving the CARI guideline targets included nurse-driven iron management protocols, use of an iron management decision aid, fewer nephrologists per dialysis unit, and a "proactive" (actively keeping iron levels within target range) rather than "reactive" (only reacting if iron levels are out of the range) protocol.
CONCLUSIONS: Variability in achievement of iron targets, despite the availability of a clinical practice guideline, may be explained by variability in processes of care for achieving and maintaining adequate iron parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16999671     DOI: 10.5694/j.1326-5377.2006.tb00584.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region.

Authors:  Rodolfo F Rivera; Davide Guido; Lucia Del Vecchio; Enzo Corghi; Marco D'Amico; Corrado Camerini; Donatella Spotti; Andrea Galassi; Claudio Pozzi; Giovanni Cancarini; Giuseppe Pontoriero; Francesco Locatelli
Journal:  J Nephrol       Date:  2015-12-29       Impact factor: 3.902

2.  Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce?

Authors:  Sophie Liabeuf; Karlijn J Van Stralen; Fergus Caskey; Francesca Tentori; Ronald L Pisoni; Ayesha Sajjad; Kitty J Jager; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2017-10-01       Impact factor: 5.992

3.  A pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial.

Authors:  Francisca Johanna van den Oever; Carolien F M Heetman-Meijer; Erwin Birnie; Erwin C Vasbinder; Eleonora L Swart; Yvonne C Schrama
Journal:  Pharmacol Res Perspect       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.